golcadomide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

A combination regimen consisting of **golcadomide** (a cereblon E3 ligase modulator, CELMoD), **rituximab** (a CD20-targeting monoclonal antibody), **cyclophosphamide** (an alkylating agent), **doxorubicin** (an anthracycline topoisomerase II inhibitor), **vincristine** (a vinca alkaloid mitotic inhibitor), and **prednisone** (a synthetic glucocorticoid corticosteroid). This regimen is under investigation for the treatment of non-Hodgkin lymphomas, especially high-risk or relapsed/refractory large B-cell lymphoma and follicular lymphoma. Golcadomide modulates cereblon, promoting protein degradation critical for tumor cell survival; rituximab binds CD20 to induce lysis of malignant B cells; cyclophosphamide, doxorubicin, and vincristine disrupt cancer cell DNA and cell division; prednisone induces cancer cell apoptosis and mitigates inflammation. The inclusion of golcadomide offers a novel immunomodulatory approach potentially enhancing the efficacy of standard chemoimmunotherapy[3][4].

Other names

CC-99282 + R-CHOP-21